EUVIMEDEUVIMED entdecken
Crossref

Screening Natural Phenolic Compounds for Blood‐Brain Barrier Permeability, Alongside GSK‐3 β , CK‐1 δ , and AChE Inhibition, for the Treatment of Alzheimer's Disease

Perihan Gürbüz iD, Şengül Dilem Doğan iD, Miyase Gözde Gündüz, Loreto Martínez-González, Concepción Pérez, Ana Martinez

Drug Development Research · 2025

DOI: 10.1002/ddr.70193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Perihan Gürbüz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacognosy, Faculty of Pharmacy, Erciyes University, Kayseri, Türkiye. Hauptthemen laut MEDLINE: Alzheimer Disease, Blood-Brain Barrier, Glycogen Synthase Kinase 3 beta, Cholinesterase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: The present study was supported by the Research Foundation of Erciyes University (Grant No: TSA-2022-11539)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's Disease (AD) is a neurological disorder characterized by progressive cognitive impairment and memory loss. In vitro artificial membrane permeability assays targeting the blood‐brain barrier (BBB), such as the parallel artificial membrane permeability assay (PAMPA), are useful for pre‐evaluating the BBB penetration of molecules during the early stages of drug development. Inhibitors of glycogen synthase kinase‐3 β (GSK‐3 β ), casein kinase‐1 δ (CK‐1 δ ), and acetylcholinesterase (AChE) exhibit neuroprotective effects, indicating a potential therapeutic approach for AD. This study aimed to assess the ability of 23 phenolic compounds derived from natural sources to penetrate the central nervous system (CNS) and examine their potential neuroprotective effects. Following the prediction of BBB penetration of the compounds by PAMPA, neuroprotective effects of CNS+ compounds were evaluated through in vitro inhibition of GSK‐3 β , CK‐1 δ , and AChE. Based on the data obtained, five flavonoids (hispidulin, nepetin, platanoside, apigenin, and kaempferol) and two furanocoumarins (isopimpinellin and bergapten) were predicted to penetrate the CNS. Apigenin ( API ) and kaempferol ( KEM ) exhibited the most potent dual inhibitory activity against CK‐1 δ and GSK‐3 β . Furthermore, API and KEM did not exhibit cytotoxic effects in SH‐SY5Y cells. Molecular modeling studies, including molecular docking, molecular dynamics simulations, and dynophore analysis, were performed to understand the binding mechanism of these most potent compounds to their target enzymes. Overall, the current study offers a rational approach to designing new molecules inspired by natural compounds to treat Alzheimer's Disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBlood-Brain BarrierGlycogen Synthase Kinase 3 betaCholinesterase InhibitorsNeuroprotective AgentsPhenolsHumansMolecular Docking SimulationAcetylcholinesterasePermeability

Stichwörter der Autor:innen

apigeninblood‐brain barrierdietary flavonoidskaempferolmolecular modelingneuroprotection

Substanzen

Glycogen Synthase Kinase 3 betaCholinesterase InhibitorsNeuroprotective AgentsPhenolsAcetylcholinesterase

Autor:innen und Institutionen

  • Department of Pharmacognosy, Faculty of Pharmacy, Erciyes University, Kayseri, Türkiye.
  • Department of Basic Sciences, Faculty of Pharmacy, Erciyes University, Kayseri, Türkiye.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Türkiye.
  • Centro de Investigaciones Biologicas, CSIC, Madrid, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
  • Medicinal Chemistry Institute-CSIC, Madrid, Spain.

ORCID-Profile: Perihan Gürbüz, Şengül Dilem Doğan

Förderung

  • The present study was supported by the Research Foundation of Erciyes University (Grant No: TSA-2022-11539).

Zitieren

APA

Gürbüz, P., Doğan, Ş. D., Gündüz, M. G., Martínez-González, L., Pérez, C., & Martinez, A. (2025). Screening Natural Phenolic Compounds for Blood‐Brain Barrier Permeability, Alongside GSK‐3 β , CK‐1 δ , and AChE Inhibition, for the Treatment of Alzheimer's Disease. Drug Development Research. https://doi.org/10.1002/ddr.70193

Vancouver

Gürbüz P, Doğan ŞD, Gündüz MG, Martínez-González L, Pérez C, Martinez A. Screening Natural Phenolic Compounds for Blood‐Brain Barrier Permeability, Alongside GSK‐3 β , CK‐1 δ , and AChE Inhibition, for the Treatment of Alzheimer's Disease. Drug Development Research. 2025. doi:10.1002/ddr.70193

BibTeX
@article{Grbz2025,
  author = {Gürbüz, Perihan and Doğan, Şengül Dilem and Gündüz, Miyase Gözde and Martínez-González, Loreto and Pérez, Concepción and Martinez, Ana},
  title = {Screening Natural Phenolic Compounds for Blood‐Brain Barrier Permeability, Alongside GSK‐3 β , CK‐1 δ , and AChE Inhibition, for the Treatment of Alzheimer's Disease},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70193}
}
Kostenlos starten →